Cargando…
An update on the use of Atripla(®) in the treatment of HIV in the United States
Atripla(®) (Gilead Sciences Inc, Foster City, CA, USA and Bristol-Myers Squibb, New York City, NY, USA) is a coformulated single pill composed of efavirenz, emtricitabine, and tenofovir disoproxil, intended as a once-daily potent combination antiretroviral therapeutic agent. Its efficacy is equivale...
Autores principales: | Horberg, Michael A, Klein, Daniel B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218697/ https://www.ncbi.nlm.nih.gov/pubmed/22096391 |
Ejemplares similares
-
Atripla™ – HIV therapy in one pill
por: Julg, Boris, et al.
Publicado: (2008) -
Atripla(R)/anti-TB combination in TB/HIV patients. Drug in focus
por: Semvua, Hadija H, et al.
Publicado: (2011) -
“One pill, once daily”: what clinicians need to know about Atripla™
por: Clay, Patrick G, et al.
Publicado: (2008) -
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
por: Mocroft, A., et al.
Publicado: (2014) -
Membranous Nephropathy in a Patient with Human Immunodeficiency Virus Shortly After Initiation of HAART with Atripla
por: Rawala, Muhammad Shabbir, et al.
Publicado: (2019)